NASDAQ : ENTA
Enanta Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.71 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 311.93M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 311.93M |
| Enterprise Value | 282.48M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 29.13M |
| Shares Outstanding | 29.13M |
| Shares Change (YoY) | +27.12% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 4.54% |
| Owned by Institutions (%) | 76.16% |
| Float | 22.52M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.78 |
| Forward PS | 5.03 |
| PB Ratio | 3.09 |
| P/TBV Ratio | 3.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.76 |
| Quick Ratio | 3.62 |
| Debt / Equity | 1.80 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.55 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -70.12% |
| Return on Assets (ROA) | -12.28% |
| Return on Invested Capital (ROIC) | -50.40% |
| Return on Capital Employed (ROCE) | -24.20% |
| Weighted Average Cost of Capital (WACC) | 8.09% |
| Revenue Per Employee | $543,817 |
| Profits Per Employee | -$526,917 |
| Employee Count | 120 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 99,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.96 |
| 52-Week Price Change | +0.75% |
| 50-Day Moving Average | 12.53 |
| 200-Day Moving Average | 13.20 |
| Relative Strength Index (RSI) | 36.65 |
| Average Volume (20 Days) | 229,122 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.27M |
| Short Previous Month | 2.55M |
| Short % of Shares Out | 7.78% |
| Short % of Float | 10.06% |
| Short Ratio (days to cover) | 8.27 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 65.26M |
| Gross Profit | 65.26M |
| Operating Income | -58.73M |
| Pretax Income | -63.13M |
| Net Income | -63.23M |
| EBITDA | -53.82M |
| EBIT | -58.73M |
| Loss Per Share | -$2.34 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 189.51M |
| Total Debt | 182.04M |
| Net Cash | 29.45M |
| Net Cash Per Share | $1.01 |
| Equity (Book Value) | 101.07M |
| Book Value Per Share | 3.47 |
| Working Capital | 149.45M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -35.32M |
| Capital Expenditures | -1.62M |
| Depreciation & Amortization | 4.91M |
| Net Borrowing | n/a |
| Free Cash Flow | -36.94M |
| FCF Per Share | -$1.27 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -89.99% |
| Pretax Margin | -96.74% |
| Profit Margin | -96.89% |
| EBITDA Margin | -82.47% |
| EBIT Margin | -89.99% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -27.12% |
| Shareholder Yield | -27.12% |
| Earnings Yield | -21.82% |
| FCF Yield | -11.84% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $21.83 |
| Price Target Difference | 103.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 9.76% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.94 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |